Search results
Results from the WOW.Com Content Network
The Wadsworth Center, originally the New York State's Antitoxin Laboratory, was established in 1901. Its mission was to standardize and manufacture antitoxin, which was for the treatment of communicable diseases such as diphtheria and anthrax. In 1914, the Antitoxin Laboratory was designated the Division of Laboratories and Research.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 31 ] [ 28 ] [ 32 ] [ 33 ] It is specifically used for cancer that is HER2 receptor positive . [ 31 ]
The main laboratory building of the IBM Research Center in Yorktown Heights, New York. The Thomas J. Watson Research Center is the headquarters for IBM Research. Its main laboratory is in Yorktown Heights, New York, 38 miles (61 km) north of New York City. It also operates facilities in Cambridge, Massachusetts and Albany, New York.
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
Inaugurated in 1991 as Albany Molecular Research, Inc., AMRI was founded by Thomas E. D’Ambra, Ph.D. and Chester Opalka. As AMRI, the company was a publicly traded company on the NASDAQ from 1999 until 2017. [3]
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, [6] and in January 2018, the City of New ...
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.